WARNING: THE FOLLOWING IMAGES CONTAIN GRAPHIC CONTENT.

 

CONDITIONS TREATED/CASE STUDIES

The following are some conditions treated with Viabecline and their respective case studies.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. Viabecline is NOT FDA approved to treat Psoriasis and Eczema but has been shown to relieve the symptoms associated with those disease by preventing secondary infection.

 
 
 

PAINFUL SORE ON THE LIP:

 
 BEFORE

BEFORE

 AFTER: 2 DAYS LATER

AFTER: 2 DAYS LATER

 
 

CHRONIC INFECTION ON THE BOTTOM OF THE FOOT:

 
 
 

ACNE CASE STUDY:

 
 AFTER: 2 WEEKS OF TREATMENT

AFTER: 2 WEEKS OF TREATMENT

 
 

ECZEMA CASE STUDY:

 
 PRIOR TO TREATMENT WITH VIABECLINE

PRIOR TO TREATMENT WITH VIABECLINE

 DAY 1: (1 APPLICATION) Dry, scaly patches starting to clear.

DAY 1: (1 APPLICATION) Dry, scaly patches starting to clear.

 DAY 21: 10 APPLICATIONS. 1X EVERY OTHER NIGHT.

DAY 21: 10 APPLICATIONS. 1X EVERY OTHER NIGHT.

 
 

DIABETIC FOOT WOUND:

 
 BEFORE: DEEP NON-HEALING WOUND

BEFORE: DEEP NON-HEALING WOUND

 AFTER: 32 DAYS LATER, HEALED

AFTER: 32 DAYS LATER, HEALED

 BEFORE: DEEP NON-HEALING WOUND

BEFORE: DEEP NON-HEALING WOUND

 AFTER: COMPLETE CLOSURE AFTER 3 MONTHS

AFTER: COMPLETE CLOSURE AFTER 3 MONTHS

 
 

POST-OP SURGICAL WOUND: (8 MONTHS OLD)

 
 BEFORE: 04/12/2014

BEFORE: 04/12/2014

 AFTER: 06/04/2014

AFTER: 06/04/2014

 
 

CHRONIC SKIN INFECTION:

 
 
 

DIABETIC FOOT INFECTION:

 
 INFECTION: DAY 1

INFECTION: DAY 1

 INFECTION: DAY 2

INFECTION: DAY 2

 AFTER: INFECTION - DAY 22

AFTER: INFECTION - DAY 22

 
 

PSORIASIS CASE STUDY: